Corient Private Wealth LP Invests $1.91 Million in Precigen, Inc. $PGEN

Corient Private Wealth LP bought a new stake in Precigen, Inc. (NASDAQ:PGEN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 334,802 shares of the biotechnology company’s stock, valued at approximately $1,908,000.

Other institutional investors also recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in Precigen by 216.9% during the first quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 43,245 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Precigen by 12.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company’s stock worth $122,000 after buying an additional 9,043 shares during the period. Strs Ohio purchased a new position in Precigen during the 1st quarter valued at about $70,000. Geode Capital Management LLC grew its position in Precigen by 7.7% during the second quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company’s stock valued at $5,325,000 after purchasing an additional 269,580 shares in the last quarter. Finally, Creative Planning grew its holdings in shares of Precigen by 127.8% during the 2nd quarter. Creative Planning now owns 94,291 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 52,901 shares in the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Precigen

In other news, CFO Harry Thomasian, Jr. sold 100,000 shares of Precigen stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $6.06, for a total transaction of $606,000.00. Following the sale, the chief financial officer owned 254,535 shares of the company’s stock, valued at approximately $1,542,482.10. This trade represents a 28.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Sabzevari sold 346,836 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $5.89, for a total value of $2,042,864.04. Following the sale, the chief executive officer owned 3,768,872 shares in the company, valued at approximately $22,198,656.08. This represents a 8.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 991,271 shares of company stock worth $6,208,620 over the last 90 days. Insiders own 41.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Zacks Research upgraded Precigen from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 5th. Citizens Jmp upped their price target on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Wall Street Zen upgraded Precigen from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Citigroup reissued an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Precigen presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Precigen Stock Up 1.9%

NASDAQ PGEN opened at $7.14 on Friday. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58. The firm has a 50-day simple moving average of $6.18 and a 200 day simple moving average of $4.81. Precigen, Inc. has a twelve month low of $2.99 and a twelve month high of $7.72. The stock has a market cap of $2.55 billion, a PE ratio of -6.87 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The firm had revenue of $54.98 million for the quarter, compared to analyst estimates of $27.98 million. Precigen’s quarterly revenue was up 6322.7% compared to the same quarter last year. On average, research analysts forecast that Precigen, Inc. will post 0.25 EPS for the current year.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.